MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

KVUE · NYSE

Kenvue Inc.

Consumer Discretionary · Specialty Chemicals

Reference price$19.75As of Jul 28, 2026
Market capitalization$37.92B
52-week range$14.02–$22.74
S&P 500 portfolio weight0.06%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$18.00-8.9% vs. reference
Average$19.40-1.8% vs. reference
High$21.00+6.3% vs. reference
0 Buy6 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 6, 2026Jun 2026
Consensus EPS$0.323 estimates
Expected range$0.27–$0.35Low to high EPS
Dec 2026$1.16Street EPS consensus
Dec 2027$1.23Street EPS consensus
Dec 2028$1.32Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 28, 2025.

MetricCurrentPrior
Revenue-2.1% YoY$15.12B$15.46B
Operating income$2.41B$1.84B
Net income$1.47B$1.03B
Operating cash flow$2.2B$1.77B
Capital expenditures($0.48B)($0.43B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

RTTNews

FDA Clears Kenvue's TYLENOL With Naproxen, First OTC Fixed-Dose Combination

NASDAQ.com

After Hours Most Active for Jul 20, 2026 : NVDA, CMCSA, INTC, HDB, KVUE, AAPL, WMT, PLTR, DVN, VZ, ESI, UPS

The Motley Fool

An Overlooked Dividend King With a 54-Year Winning Streak Worth Buying Now

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.